(31-03-12) Effects of n?3 PUFA supplementation on plasma soluble adhesion molecules: a meta-analysis of randomized controlled trials1,2,3

1. Yang Yang,
2. Na Lu,
3. Dongmei Chen,
4. Lin Meng,
5. Yang Zheng, and
6. Rutai Hui
+Author Affiliations
1. 1From the Department of Cardiology, Bethune First Hospital of Jilin University, China (YY, NL, DC, LM, and YZ), and Sino-German Laboratory for Molecular Medicine, Hypertension Division, FuWai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (RH).
+Author Notes
? ↵2 Supported by International S&T Cooperation Program of China (no. 2009DFB30050 to RH).
? ↵3 Address correspondence to R Hui, Sino-German Laboratory for Molecular Medicine, Hypertension Division, FuWai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Beijing 100037, PR China. E-mail: [email protected]; or to Y Zheng, Department of Cardiology, Bethune First Hospital of Jilin University, 71 Xinmin Street, Changchun City, Jilin Province, 130021, PR China. E-mail: [email protected].
Abstract
Background: Previous studies indicate that oral supplementation with n?3 PUFA protects against atherosclerotic disease by inhibiting inflammatory processes, which underlie atherosclerosis and are reflected by the plasma concentrations of soluble adhesion molecules. However, consistent results were not obtained among studies.
Objective: The objective was to assess the effects of n?3 PUFA supplementation on plasma concentrations of soluble adhesion molecules.
Design: We conducted a meta-analysis of randomized controlled trials identified from PubMed, Embase, the Cochrane Library, and reference lists of relevant articles and reviews.
Results: Eighteen studies were included. n?3 PUFA supplementation reduced plasma concentrations of soluble intercellular adhesion molecule-1 [sICAM-1; weighted mean difference (WMD): ?5.17; 95% CI: ?10.07, ?0.27; P = 0.04] but had no significant effects on soluble vascular cell adhesion molecule-1 (WMD: ?5.90; 95% CI: ?17.63, 5.84; P = 0.32), soluble P-selectin (WMD: ?1.53; 95% CI: ?4.33, 1.28; P = 0.29), or soluble E-selectin (WMD: 0.46; 95% CI: ?1.54, 2.46; P = 0.65). Subgroup analysis stratified by the subjects? health status showed that n?3 PUFA supplementation reduced sICAM-1 concentrations in healthy subjects (WMD: ?8.87; 95% CI: ?15.20, ?2.53; P = 0.006; heterogeneity test: I2 = 0%, P = 0.76) and in subjects with dyslipidemia (WMD: ?15.31; 95% CI: ?26.82, ?3.81; P = 0.009; heterogeneity test: I2 = 26%, P = 0.26).
Conclusions: n?3 PUFA supplementation can reduce plasma concentrations of sICAM-1. The effect is identified in both healthy subjects and subjects with dyslipidemia, which supports the hypothesis that n?3 PUFA can be supplemented as a primary or secondary means for preventing the development as well as the progression of atherosclerosis.

Source: Am J Clin Nutr April 2012 vol. 95 no. 4 972-980

News

---

In evidenza

"L'informazione presente nel sito serve a migliorare, e non a sostituire, il rapporto medico-paziente."

Per coloro che hanno problemi di salute si consiglia di consultare sempre il proprio medico curante.